论文标题
COVID-19中临床结果的免疫学决定因素:定量的观点
Immunological determinants of clinical outcomes in COVID-19: A quantitative perspective
论文作者
论文摘要
严重的急性呼吸综合征冠状病毒2(SARS-COV-2)具有可变的临床表现,范围从无症状到细胞因子风暴的严重疾病。全球的死亡率也不同,范围为0.5-13%。这种变异可能是由于病原体和宿主因素引起的。宿主因素可能包括免疫反应基因的遗传差异以及HLA和KIR同型的变异。为了更好地了解,这些遗传变异在免疫反应基因在对SARS-COV-2的免疫反应中观察到的差异可能会产生什么,这是对考虑到病毒生长的幅度的动态系统模型的定量分析,以及随后的天生和适应性反应,以实现感染的控制所需。基于这个广泛的定量框架,可能会认为,有症状至严重症状的covid19的范围代表了先天和适应性免疫反应之间的平衡。在无症状的患者中,迅速和适当的适应性免疫反应激素感染,而在患有严重症状的患者中,适应性反应不足会导致持续的病毒复制促进的失控的细胞因子级联反应。先天和适应性免疫反应的各个组成部分中的多态性可能会导致免疫反应动力学改变,从而导致疾病严重程度。了解这种遗传变异如何改变对SARS-COV-2感染的反应对于制定成功的治疗策略至关重要。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a variable clinical presentation that ranges from asymptomatic, to severe disease with cytokine storm. The mortality rates also differ across the globe, ranging from 0.5-13%. This variation is likely due to both pathogen and host factors. Host factors may include genetic differences in the immune response genes as well as variation in HLA and KIR allotypes. To better understand what impact these genetic variants in immune response genes may have in the differences observed in the immune response to SARS-CoV-2, a quantitative analysis of a dynamical systems model that considers both, the magnitude of viral growth, and the subsequent innate and adaptive response required to achieve control of infection is considered. Based on this broad quantitative framework it may be posited that the spectrum of symptomatic to severely symptomatic presentations of COVID19 represents the balance between innate and adaptive immune responses. In asymptomatic patients, prompt and adequate adaptive immune response quells infection, whereas in those with severe symptoms a slower inadequate adaptive response leads to a runaway cytokine cascade fueled by ongoing viral replication. Polymorphisms in the various components of the innate and adaptive immune response may cause altered immune response kinetics that would result in variable severity of illness. Understanding how this genetic variation may alter the response to SARS-CoV-2 infection is critical to develop successful treatment strategies.